Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on May 27, 2025
Strüngmann Award Committee Announces 2025 Finalists Recognizing Outstanding Life Science Entrepreneurs in the DACH Region
GlobeNewswire
·
May 27, 2025
The selected finalists have demonstrated entrepreneurial execution and translational potential for a range of scientific approaches The winner(s) will be officially announced on July 3, 2025, and will receive an EUR 100,000 cash prize Munich, Germany, May …
Juri Biosciences, a TCG Labs Soleil Portfolio Company, and EpimAb Biotherapeutics Enter into a Worldwide Licensing Agreement for KLK2-Directed T-Cell Engager in Metastatic Prostate Cancer
GlobeNewswire
·
May 27, 2025
SAN FRANCISCO and SHANGHAI, May 27, 2025 (GLOBE NEWSWIRE) -- TCG Labs Soleil, a venture firm integrating dedicated capital with an in-house biotech R…
ITM Secures Up to $262.5m in Non-dilutive Debt Financing with Blue Owl Managed Funds
GlobeNewswire
·
May 27, 2025
Debt capital to support commercial readiness and potential U.S. launch of n.c.a. 177Lu-edotreotide (ITM-11), following positive Phase 3 results Flexible funding structure enables continued advancement of ITM’s targeted radiopharmaceutical pipeline and …
Epitopea Announces Nature Cancer Paper on Novel Immunotherapy Targets in Melanoma and NSCLC
GlobeNewswire
·
May 27, 2025
MONTREAL and CAMBRIDGE, United Kingdom, May 27, 2025 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapy company, and Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, a leading Canadian research …
Epitopea annonce un article dans Nature Cancer sur de nouvelles cibles d'immunothérapie dans le mélanome et le cancer du poumon non à petites cellules (NSCLC)
GlobeNewswire
·
May 27, 2025
MONTRÉAL et CAMBRIDGE, Royaume-Uni, 27 mai 2025 (GLOBE NEWSWIRE) -- Epitopea, une société transatlantique spécialisée en immunothérapie des cancers, et l'Institut de recherche en immunologie et en cancérologie (IRIC) de l'Université de Montréal, une …
C4X Discovery receives latest milestone payment from Sanofi
GlobeNewswire
·
May 27, 2025
€8 million milestone payment triggered by pre-clinical progression in oral IL-17A inhibitor programme 27 May 2025 – C4X Discovery Holdings Ltd (“C4XD”), a pioneering Drug Discovery company, today announces that it has received a milestone payment of €8 …
dacadoo Launches Generation 5 of Its Award-Winning Digital Health Engagement Platform
GlobeNewswire
·
May 27, 2025
Zurich, CH, May 27, 2025 (GLOBE NEWSWIRE) -- dacadoo, a global leader in digital health engagement technology since 2010 with over 100 granted patents, announces the launch of Generation 5 of its Digital Health EngagementPlatform (DHEP). This next- …
Salvia BioElectronics Secures $60M in Oversubscribed Series B to Bring its Pioneering Migraine Therapy to Market
GlobeNewswire
·
May 27, 2025
Series B funding round led by Innovation Industries, with participation from Invest-NL, EIC Fund, and existing investors Inkef, Panakès Partners, SHS Capital, Dolby Family Ventures, Brabant Development Agency (BOM) and Thuja Capital. Proceeds will fund …
Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan
GlobeNewswire
·
May 27, 2025
Exclusive Japanese partner Kowa has received regulatory approval to initiate Phase 3 clinical trials on NCX 470 for the treatment of ocular hypertension in Japan Milestone payments from Kowa totaling €3 million expected to be received by Nicox in 2025 …
Nicox annonce jusqu’à 3 millions d’euros de paiements d’étapes de la part de Kowa en 2025, alors que NCX 470 se prépare à entrer en essais cliniques de Phase 3 au Japon
GlobeNewswire
·
May 27, 2025
27 mai 2025 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société internationale spécialisée en ophtalmologie, annonce aujourd’hui que son partenaire exclusif au Japon pour NCX …
Augustine Therapeutics announces first patient dosed in Phase I clinical trial evaluating lead candidate AGT-100216 for the treatment of Charcot-Marie-Tooth disease
GlobeNewswire
·
May 27, 2025
AGT-100216 is the first HDAC6 inhibitor from Augustine’s pipeline to enter clinical trials LEUVEN, Belgium – 27 May 2025– Augustine Therapeutics NV (“Augustine” or “the Company”), a biotechnology company focused on developing new therapies for …
Press Release: Sanofi completes acquisition of DR-0201
GlobeNewswire
·
May 27, 2025
Sanofi completes acquisition of DR-0201 Paris, May 27, 2025. Sanofi announces the completion of its acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a private clinical-stage biopharmaceutical company. The acquisition …
Communiqué de presse : Sanofi finalise l’acquisition du DR-0201
GlobeNewswire
·
May 27, 2025
Sanofi finalise l’acquisition du DR-0201 Paris, le 27 mars 2025. Sanofi annonce la finalisation de l’acquisition du DR-0201, un anticorps bispécifique ciblé qui engage les cellules myéloïdes, à Dren Bio, Inc., société biopharmaceutique privée au stade …
Press release: Sequana Medical Secures Additional Convertible Financing of EUR 6.3 Million from SFPIM and Other Existing Shareholders
GlobeNewswire
·
May 27, 2025
Sequana Medical Secures Additional Convertible Financing of EUR 6.3 Million from SFPIM and Other Existing Shareholders Continued strong support from major shareholders alfapump® US commercial launch remains on track for Q3 2025 through specialty …